May 15
|
Adaptimmune Reports Q1 2024 Financial and Business Updates
|
May 15
|
Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital
|
May 1
|
Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024
|
Apr 15
|
Adaptimmune (ADAP) Down on End of Collaboration With Roche
|
Apr 12
|
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
|
Apr 12
|
Roche, Adaptimmune part ways on cell therapy research
|
Mar 27
|
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
|
Mar 8
|
Adaptimmune Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
|
Mar 7
|
Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results
|
Mar 7
|
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript
|
Mar 6
|
Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
|
Jan 17
|
Adaptimmune Therapeutics (NASDAQ:ADAP shareholders incur further losses as stock declines 22% this week, taking three-year losses to 88%
|
Jan 16
|
Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
|
Dec 7
|
Positive week for Adaptimmune Therapeutics plc (NASDAQ:ADAP) institutional investors who lost 68% over the past year
|
Dec 6
|
Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
|
Nov 30
|
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND
|
Nov 29
|
Adaptimmune Receives Transfer of IND for Lete-cel Program
|
Nov 13
|
Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
Nov 13
|
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2023 Earnings Call Transcript
|
Nov 9
|
Forecast: Analysts Think Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Business Prospects Have Improved Drastically
|